http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 27 Oct 2026 08:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Entera+Bio+Ltd.+++++++++++For%3A+Oct+27/27237099.html si-local-file:///var/storage/secattach/20261027/27237099.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Entera+Bio+Ltd.+++++++++++For%3A+Oct+27/27237099.html Tue, 27 Oct 2026 08:01:00 -0400 ENTX http://www.streetinsider.com/Board+Changes/Entera+Bio+names+Organon+CMO+to+its+board+of+directors/27236982.html <p>Entera Bio Ltd. (NASDAQ: ENTX) announced the appointment of Juan Camilo Arjona Ferreira, M.D., to its board of directors, effective December 1, 2026. Dr. Arjona Ferreira will replace Haya Taitel, who is stepping down from the board.</p> <p>Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN), where he oversees the company's global research and development organization, including early- and late-stage development, regulatory affairs, pharmacovigilance, and medical affairs. Prior to Organon, he held the role of Chief Medical Officer at Myovant Sciences, leading clinical development and medical affairs in women's http://www.streetinsider.com/Board+Changes/Entera+Bio+names+Organon+CMO+to+its+board+of+directors/27236982.html Tue, 27 Oct 2026 08:00:35 -0400 ENTX MRK OGN http://www.streetinsider.com/Board+Changes/Entera+Bio+names+Organon+CMO+to+its+board+of+directors/27236982.html <p>Entera Bio Ltd. (NASDAQ: ENTX) announced the appointment of Juan Camilo Arjona Ferreira, M.D., to its board of directors, effective December 1, 2026. Dr. Arjona Ferreira will replace Haya Taitel, who is stepping down from the board.</p> <p>Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN), where he oversees the company's global research and development organization, including early- and late-stage development, regulatory affairs, pharmacovigilance, and medical affairs. Prior to Organon, he held the role of Chief Medical Officer at Myovant Sciences, leading clinical development and medical affairs in women's http://www.streetinsider.com/Board+Changes/Entera+Bio+names+Organon+CMO+to+its+board+of+directors/27236982.html Tue, 27 Oct 2026 08:00:35 -0400 ENTX MRK OGN http://www.streetinsider.com/Board+Changes/Entera+Bio+names+Organon+CMO+to+its+board+of+directors/27236982.html <p>Entera Bio Ltd. (NASDAQ: ENTX) announced the appointment of Juan Camilo Arjona Ferreira, M.D., to its board of directors, effective December 1, 2026. Dr. Arjona Ferreira will replace Haya Taitel, who is stepping down from the board.</p> <p>Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN), where he oversees the company's global research and development organization, including early- and late-stage development, regulatory affairs, pharmacovigilance, and medical affairs. Prior to Organon, he held the role of Chief Medical Officer at Myovant Sciences, leading clinical development and medical affairs in women's http://www.streetinsider.com/Board+Changes/Entera+Bio+names+Organon+CMO+to+its+board+of+directors/27236982.html Tue, 27 Oct 2026 08:00:35 -0400 ENTX MRK OGN http://www.streetinsider.com/Press+Releases/Entera+Appoints+Global+Research+and+Development+Leader+Dr.+Juan+Camilo+Arjona+Ferreira+to+Its+Board+of+Directors/27236887.html <p align="center"><em>Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon &amp; Co. (NYSE: OGN)</em></p> <p align="center"><em>He joins Entera with two decades of clinical development, regulatory execution, and women’s health leadership with roles at Myovant, Shionogi and Merck prior to Organon</em></p> <p>TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of clinical leader Juan Camilo Arjona Ferreira, M.D., to its Board of Directors, effective December 1, 2026. Dr. http://www.streetinsider.com/Press+Releases/Entera+Appoints+Global+Research+and+Development+Leader+Dr.+Juan+Camilo+Arjona+Ferreira+to+Its+Board+of+Directors/27236887.html Tue, 27 Oct 2026 08:00:00 -0400 ENTX MRK OGN http://www.streetinsider.com/Globe+Newswire/Entera+Appoints+Global+Research+and+Development+Leader+Dr.+Juan+Camilo+Arjona+Ferreira+to+Its+Board+of+Directors/27236887.html <p align="center"><em>Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon &amp; Co. (NYSE: OGN)</em></p> <p align="center"><em>He joins Entera with two decades of clinical development, regulatory execution, and women’s health leadership with roles at Myovant, Shionogi and Merck prior to Organon</em></p> <p>TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of clinical leader Juan Camilo Arjona Ferreira, M.D., to its Board of Directors, effective December 1, 2026. Dr. http://www.streetinsider.com/Globe+Newswire/Entera+Appoints+Global+Research+and+Development+Leader+Dr.+Juan+Camilo+Arjona+Ferreira+to+Its+Board+of+Directors/27236887.html Tue, 27 Oct 2026 08:00:00 -0400 ENTX MRK OGN http://www.streetinsider.com/Press+Releases/Entera+Appoints+Global+Research+and+Development+Leader+Dr.+Juan+Camilo+Arjona+Ferreira+to+Its+Board+of+Directors/27236887.html <p align="center"><em>Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon &amp; Co. (NYSE: OGN)</em></p> <p align="center"><em>He joins Entera with two decades of clinical development, regulatory execution, and women’s health leadership with roles at Myovant, Shionogi and Merck prior to Organon</em></p> <p>TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of clinical leader Juan Camilo Arjona Ferreira, M.D., to its Board of Directors, effective December 1, 2026. Dr. http://www.streetinsider.com/Press+Releases/Entera+Appoints+Global+Research+and+Development+Leader+Dr.+Juan+Camilo+Arjona+Ferreira+to+Its+Board+of+Directors/27236887.html Tue, 27 Oct 2026 08:00:00 -0400 ENTX MRK OGN http://www.streetinsider.com/Globe+Newswire/Entera+Appoints+Global+Research+and+Development+Leader+Dr.+Juan+Camilo+Arjona+Ferreira+to+Its+Board+of+Directors/27236887.html <p align="center"><em>Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon &amp; Co. (NYSE: OGN)</em></p> <p align="center"><em>He joins Entera with two decades of clinical development, regulatory execution, and women’s health leadership with roles at Myovant, Shionogi and Merck prior to Organon</em></p> <p>TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of clinical leader Juan Camilo Arjona Ferreira, M.D., to its Board of Directors, effective December 1, 2026. Dr. http://www.streetinsider.com/Globe+Newswire/Entera+Appoints+Global+Research+and+Development+Leader+Dr.+Juan+Camilo+Arjona+Ferreira+to+Its+Board+of+Directors/27236887.html Tue, 27 Oct 2026 08:00:00 -0400 ENTX MRK OGN http://www.streetinsider.com/Press+Releases/Entera+Appoints+Global+Research+and+Development+Leader+Dr.+Juan+Camilo+Arjona+Ferreira+to+Its+Board+of+Directors/27236887.html <p align="center"><em>Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon &amp; Co. (NYSE: OGN)</em></p> <p align="center"><em>He joins Entera with two decades of clinical development, regulatory execution, and women’s health leadership with roles at Myovant, Shionogi and Merck prior to Organon</em></p> <p>TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of clinical leader Juan Camilo Arjona Ferreira, M.D., to its Board of Directors, effective December 1, 2026. Dr. http://www.streetinsider.com/Press+Releases/Entera+Appoints+Global+Research+and+Development+Leader+Dr.+Juan+Camilo+Arjona+Ferreira+to+Its+Board+of+Directors/27236887.html Tue, 27 Oct 2026 08:00:00 -0400 ENTX MRK OGN http://www.streetinsider.com/Globe+Newswire/Entera+Appoints+Global+Research+and+Development+Leader+Dr.+Juan+Camilo+Arjona+Ferreira+to+Its+Board+of+Directors/27236887.html <p align="center"><em>Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon &amp; Co. (NYSE: OGN)</em></p> <p align="center"><em>He joins Entera with two decades of clinical development, regulatory execution, and women’s health leadership with roles at Myovant, Shionogi and Merck prior to Organon</em></p> <p>TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of clinical leader Juan Camilo Arjona Ferreira, M.D., to its Board of Directors, effective December 1, 2026. Dr. http://www.streetinsider.com/Globe+Newswire/Entera+Appoints+Global+Research+and+Development+Leader+Dr.+Juan+Camilo+Arjona+Ferreira+to+Its+Board+of+Directors/27236887.html Tue, 27 Oct 2026 08:00:00 -0400 ENTX MRK OGN http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Entera+Bio+Ltd.+++++++++++For%3A+Oct+14/27187143.html si-local-file:///var/storage/secattach/20261014/27187143.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Entera+Bio+Ltd.+++++++++++For%3A+Oct+14/27187143.html Wed, 14 Oct 2026 16:05:00 -0400 ENTX http://www.streetinsider.com/FDA/Entera+Bio+shares+Phase+2+data+and+Phase+3+design+for+oral+PTH+tablet/27176874.html <p>Entera Bio Ltd. (NASDAQ: ENTX) presented post-hoc Phase 2 data and its Phase 3 study design for EB613, an oral PTH(1-34) tablet being developed for postmenopausal osteoporosis, at the American Society for Bone and Mineral Research Annual Meeting held October 9-12, 2026, in Boston.</p> <p>The post-hoc analysis from the Phase 2 trial examined outcomes in postmenopausal women with baseline T-scores of ≤-2.5 versus those with T-scores of >-2.5. Among women with T-scores of ≤-2.5 treated with EB613 2.5 mg daily, placebo-adjusted bone mineral density increases at six months were 4.23% at the total hip and 4.22% at the lumbar spine. Women http://www.streetinsider.com/FDA/Entera+Bio+shares+Phase+2+data+and+Phase+3+design+for+oral+PTH+tablet/27176874.html Tue, 13 Oct 2026 07:01:05 -0400 ENTX http://www.streetinsider.com/FDA/Entera+Bio+shares+Phase+2+EB613+bone+density+data+at+ASBMR+meeting/27176870.html <p>Entera Bio Ltd. (NASDAQ: ENTX) presented post-hoc Phase 2 data and a Phase 3 study design for its oral osteoporosis tablet candidate EB613 at the American Society for Bone and Mineral Research Annual Meeting, held October 9-12, 2026, in Boston.</p> <p>The post-hoc analysis examined results from a previously completed Phase 2 trial that randomized 161 postmenopausal women to placebo or one of four EB613 dose levels for six months. The analysis focused on participants receiving EB613 2.5 mg daily, comparing outcomes by baseline T-score.</p> <p>Women with baseline T-scores of ≤-2.5, indicating osteoporosis, showed mean placebo-adjusted bone mineral density increases of 4.23% at http://www.streetinsider.com/FDA/Entera+Bio+shares+Phase+2+EB613+bone+density+data+at+ASBMR+meeting/27176870.html Tue, 13 Oct 2026 07:01:01 -0400 ENTX http://www.streetinsider.com/Press+Releases/Entera+Presents+Markedly+Enhanced+Anabolic+Effects+of+EB613+%28First-in-Class+Oral+PTH%281-34%29+Tablet%29+in+Postmenopausal+Women+with+Osteoporosis+at+High+Risk+of+Fracture+and+Showcases+Phase+3+Design+at+AS/27176774.html <p align="center"><i>Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of &gt;-2.5 (osteopenia)</i></p> <p align="center"><i>These findings support the potential benefit of EB613 in postmenopausal women with osteoporosis at high risk for fracture - consistent with the study population to be enrolled in Entera’s Phase 3 study </i></p> <p align="justify">TEL AVIV, Israel, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced data http://www.streetinsider.com/Press+Releases/Entera+Presents+Markedly+Enhanced+Anabolic+Effects+of+EB613+%28First-in-Class+Oral+PTH%281-34%29+Tablet%29+in+Postmenopausal+Women+with+Osteoporosis+at+High+Risk+of+Fracture+and+Showcases+Phase+3+Design+at+AS/27176774.html Tue, 13 Oct 2026 07:00:00 -0400 ENTX http://www.streetinsider.com/Globe+Newswire/Entera+Presents+Markedly+Enhanced+Anabolic+Effects+of+EB613+%28First-in-Class+Oral+PTH%281-34%29+Tablet%29+in+Postmenopausal+Women+with+Osteoporosis+at+High+Risk+of+Fracture+and+Showcases+Phase+3+Design+at+AS/27176774.html <p align="center"><i>Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of &gt;-2.5 (osteopenia)</i></p> <p align="center"><i>These findings support the potential benefit of EB613 in postmenopausal women with osteoporosis at high risk for fracture - consistent with the study population to be enrolled in Entera’s Phase 3 study </i></p> <p align="justify">TEL AVIV, Israel, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced data http://www.streetinsider.com/Globe+Newswire/Entera+Presents+Markedly+Enhanced+Anabolic+Effects+of+EB613+%28First-in-Class+Oral+PTH%281-34%29+Tablet%29+in+Postmenopausal+Women+with+Osteoporosis+at+High+Risk+of+Fracture+and+Showcases+Phase+3+Design+at+AS/27176774.html Tue, 13 Oct 2026 07:00:00 -0400 ENTX http://www.streetinsider.com/Press+Releases/Entera+Presents+Markedly+Enhanced+Anabolic+Effects+of+EB613+%28First-in-Class+Oral+PTH%281-34%29+Tablet%29+in+Postmenopausal+Women+with+Osteoporosis+at+High+Risk+of+Fracture+and+Showcases+Phase+3+Design+at+AS/27176861.html <p align="center"><i>Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of &gt;-2.5 (osteopenia)</i></p> <p align="center"><i>These findings support the potential benefit of EB613 in postmenopausal women with osteoporosis at high risk for fracture - consistent with the study population to be enrolled in Entera’s Phase 3 study </i></p> <p align="justify">TEL AVIV, Israel, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced data http://www.streetinsider.com/Press+Releases/Entera+Presents+Markedly+Enhanced+Anabolic+Effects+of+EB613+%28First-in-Class+Oral+PTH%281-34%29+Tablet%29+in+Postmenopausal+Women+with+Osteoporosis+at+High+Risk+of+Fracture+and+Showcases+Phase+3+Design+at+AS/27176861.html Tue, 13 Oct 2026 07:00:00 -0400 ENTX http://www.streetinsider.com/Globe+Newswire/Entera+Presents+Markedly+Enhanced+Anabolic+Effects+of+EB613+%28First-in-Class+Oral+PTH%281-34%29+Tablet%29+in+Postmenopausal+Women+with+Osteoporosis+at+High+Risk+of+Fracture+and+Showcases+Phase+3+Design+at+AS/27176861.html <p align="center"><i>Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of &gt;-2.5 (osteopenia)</i></p> <p align="center"><i>These findings support the potential benefit of EB613 in postmenopausal women with osteoporosis at high risk for fracture - consistent with the study population to be enrolled in Entera’s Phase 3 study </i></p> <p align="justify">TEL AVIV, Israel, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced data http://www.streetinsider.com/Globe+Newswire/Entera+Presents+Markedly+Enhanced+Anabolic+Effects+of+EB613+%28First-in-Class+Oral+PTH%281-34%29+Tablet%29+in+Postmenopausal+Women+with+Osteoporosis+at+High+Risk+of+Fracture+and+Showcases+Phase+3+Design+at+AS/27176861.html Tue, 13 Oct 2026 07:00:00 -0400 ENTX http://www.streetinsider.com/FDA/Entera+Bio+to+present+EB613+Phase+3+study+design+at+ASBMR+meeting/27163905.html <p>Entera Bio Ltd. (NASDAQ: ENTX) announced that a presentation of the clinical study design for its planned Phase 3 trial of EB613, an oral PTH(1-34) tablet for osteoporosis, has been accepted as a late-breaking poster presentation at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting in Boston, Massachusetts, running October 9-12, 2026.</p> <p>The presentation, titled "EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for the Treatment of Osteoporosis: Phase 3 Study Design," is scheduled for Sunday, October 11, 2026, from 2:00 to 3:30 p.m. ET (Presentation Number: Sun-522). It will be led by Dr. Felicia Cosman, Professor http://www.streetinsider.com/FDA/Entera+Bio+to+present+EB613+Phase+3+study+design+at+ASBMR+meeting/27163905.html Thu, 08 Oct 2026 08:00:18 -0400 ENTX http://www.streetinsider.com/Press+Releases/Entera+Bio+Announces+Additional+Presentation+of+EB613+Phase+3+Study+Design+at+the+ASBMR+2026+Annual+Meeting/27163827.html <p align="justify">TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional presentation highlighting the clinical study design for its planned Phase 3 registrational trial of EB613 (oral PTH(1-34) tablet) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9-12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts.</p> <p align="justify">The additional presentation, titled “EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for http://www.streetinsider.com/Press+Releases/Entera+Bio+Announces+Additional+Presentation+of+EB613+Phase+3+Study+Design+at+the+ASBMR+2026+Annual+Meeting/27163827.html Thu, 08 Oct 2026 08:00:00 -0400 ENTX http://www.streetinsider.com/Globe+Newswire/Entera+Bio+Announces+Additional+Presentation+of+EB613+Phase+3+Study+Design+at+the+ASBMR+2026+Annual+Meeting/27163827.html <p align="justify">TEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that an additional presentation highlighting the clinical study design for its planned Phase 3 registrational trial of EB613 (oral PTH(1-34) tablet) will be presented at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place October 9-12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts.</p> <p align="justify">The additional presentation, titled “EB613 [Oral PTH(1-34)]: The First Oral Anabolic Tablet for http://www.streetinsider.com/Globe+Newswire/Entera+Bio+Announces+Additional+Presentation+of+EB613+Phase+3+Study+Design+at+the+ASBMR+2026+Annual+Meeting/27163827.html Thu, 08 Oct 2026 08:00:00 -0400 ENTX http://www.streetinsider.com/Board+Changes/Entera+Bio+adds+former+Gilead+executive+Laura+Hamill+to+its+board/27152176.html <p>Entera Bio Ltd. (NASDAQ: ENTX) announced the appointment of Laura Hamill to its Board of Directors, effective December 1, 2026. Hamill succeeds Yonatan Malca, who is stepping down after 16 years of service.</p> <p>Hamill brings more than 35 years of biopharmaceutical commercial leadership experience. Most recently, she served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences, where she led an organization of approximately 2,500 employees responsible for $22 billion in annual revenue.</p> <p>Prior to Gilead, Hamill spent nearly two decades at Amgen in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations, where she oversaw http://www.streetinsider.com/Board+Changes/Entera+Bio+adds+former+Gilead+executive+Laura+Hamill+to+its+board/27152176.html Tue, 06 Oct 2026 08:00:50 -0400 ENTX FATE JAZZ http://www.streetinsider.com/Board+Changes/Entera+Bio+adds+former+Gilead+executive+Laura+Hamill+to+its+board/27152176.html <p>Entera Bio Ltd. (NASDAQ: ENTX) announced the appointment of Laura Hamill to its Board of Directors, effective December 1, 2026. Hamill succeeds Yonatan Malca, who is stepping down after 16 years of service.</p> <p>Hamill brings more than 35 years of biopharmaceutical commercial leadership experience. Most recently, she served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences, where she led an organization of approximately 2,500 employees responsible for $22 billion in annual revenue.</p> <p>Prior to Gilead, Hamill spent nearly two decades at Amgen in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations, where she oversaw http://www.streetinsider.com/Board+Changes/Entera+Bio+adds+former+Gilead+executive+Laura+Hamill+to+its+board/27152176.html Tue, 06 Oct 2026 08:00:50 -0400 ENTX FATE JAZZ http://www.streetinsider.com/Board+Changes/Entera+Bio+adds+former+Gilead+executive+Laura+Hamill+to+its+board/27152176.html <p>Entera Bio Ltd. (NASDAQ: ENTX) announced the appointment of Laura Hamill to its Board of Directors, effective December 1, 2026. Hamill succeeds Yonatan Malca, who is stepping down after 16 years of service.</p> <p>Hamill brings more than 35 years of biopharmaceutical commercial leadership experience. Most recently, she served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences, where she led an organization of approximately 2,500 employees responsible for $22 billion in annual revenue.</p> <p>Prior to Gilead, Hamill spent nearly two decades at Amgen in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations, where she oversaw http://www.streetinsider.com/Board+Changes/Entera+Bio+adds+former+Gilead+executive+Laura+Hamill+to+its+board/27152176.html Tue, 06 Oct 2026 08:00:50 -0400 ENTX FATE JAZZ http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Entera+Bio+Ltd.+++++++++++For%3A+Oct+06/27152169.html si-local-file:///var/storage/secattach/20261006/27152169.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Entera+Bio+Ltd.+++++++++++For%3A+Oct+06/27152169.html Tue, 06 Oct 2026 08:00:00 -0400 ENTX http://www.streetinsider.com/Press+Releases/Entera+Appoints+Global+BioPharma+Executive+Laura+Hamill+to+Its+Board+of+Directors%2C+Expanding+Commercial+Expertise/27151994.html <p><strong>Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies</strong></p><p>TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026. Ms. Hamill brings more than 35 years of global commercial, market access and business leadership experience across multiple therapeutic areas. She succeeds Yonatan Malca, who is stepping down from the Board.</p> <p>“I am delighted http://www.streetinsider.com/Press+Releases/Entera+Appoints+Global+BioPharma+Executive+Laura+Hamill+to+Its+Board+of+Directors%2C+Expanding+Commercial+Expertise/27151994.html Tue, 06 Oct 2026 08:00:00 -0400 ENTX FATE JAZZ